智通财经网·2026-01-27 08:49Core Viewpoint - The company, CanSino Biologics (06185), anticipates significant revenue growth and a turnaround in profitability by the end of 2025, driven by innovative product offerings and effective cost management [1] Financial Projections - The company expects to achieve an operating revenue of RMB 1.04 billion to RMB 1.08 billion for the fiscal year ending December 31, 2025, representing an increase of RMB 194 million to RMB 234 million compared to the previous year, which translates to a year-on-year growth of 22.88% to 27.61% [1] - The projected net profit attributable to the owners of the parent company is expected to be between RMB 24.5 million and RMB 29 million, indicating a turnaround from a loss to profitability compared to the previous year [1] - The company anticipates a net loss attributable to the owners of the parent company, excluding non-recurring gains and losses, to be between RMB 91 million and RMB 96 million [1] Strategic Focus - The company continues to implement a development strategy centered on innovation and commercialization, with the revenue from its first quadrivalent meningococcal conjugate vaccine, Manhaixin, showing sustained growth [1] - The company has made significant progress in cost reduction and efficiency improvement, effectively managing various expenses, which has led to an enhancement in gross margin [1] - The overall profitability has significantly improved, achieving a positive net profit attributable to the owners of the parent company during the reporting period [1] Research and Funding - The rapid advancement of the company's R&D projects and international collaborations has resulted in increased government grants and international funding support, contributing to substantial non-recurring gains during the reporting period [1]